The U.S. fertility diagnostic market size accounted for USD 1.42 billion in 2025 and is predicted to increase from USD 1.55 billion in 2026 to approximately USD 3.33 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035. Early evaluation is significant to detect underlying causes of fertility challenges like ovulatory dysfunction, tubal disease, endometriosis, and male factor infertility, which drives the growth of the market.
Infertility testing is a significant step to identify infections and some health conditions, such as endometriosis. This testing is done to assess the reasons for infertility among both the male and the female partner. Fertility tests provide solutions to partners having challenges conceiving. Fertility tests supports physician learn why some patients struggle to conceive. These tests give physicians an entire image of reproductive health and guide them toward the right treatment choices. Female fertility tests include blood tests, an ultrasound exam, hysterosalpingography, hysteroscopy, and sonohysterogram. Male fertility tests include semen analysis, hormone analysis, and advanced tests. Physicians suggest fertility testing after a year of ineffective conception attempts for partners under 35, and six months for those over 35. Fertility tests are a significant way to gain insights for family planning. These test results support doctors in making tailored management plans that target particular issues.
In the U.S., among women reporting infertility, the highest birth rates after infertility treatment were among Asian women (17%) and White women (13%).
| Type of Women | Birth Rate (%) |
| Asian women | 17% |
| White women | 13% |
Preimplantation genetic testing (PGT) is an advanced technology used to identify genetic irregularities in embryos created with in vitro fertilization (IVF). This testing is a diagnostic process that has become an important complement to assisted reproduction procedures. PGT has many indications, and there is a broad range of methods that are used, each with its own benefits. It is currently extensively applied to identify hundreds of genetic and chromosomal challenges in oocytes and embryos for posterior selection of the ones that are heritably transferable, thus evading the transmission of a disease to the progenies. PGT is an advanced test that includes the collection of genetic material by biopsy of an oocyte or embryo, preparation of the material, and genetic examination.
By product type, the ovulation prediction kits segment contributed the largest market share of 31% in 2025, as used by women to help predict when an egg release is likely. This is when pregnancy is most expected to occur. Ovulation kits are significant for an increase in the luteinizing hormone, which causes women to ovulate and release an egg. OPKs are more accurate than any different procedures of identifying ovulation and are 97% efficient in finding of the LH surge.
By test type, the ovulation testing segment contributed the largest U.S. fertility diagnostic market share of 30%, as ovulation tests significant advantageous for women who want to get pregnant. They spot the LH surge that happens before ovulation, helping to figure out the finest time to conceive. Ovulation kits detect an increase in the luteinizing hormone, which causes women to ovulate and release an egg.
By mode of testing, the laboratory-based testing segment held a major share of 52% in the market, as lab-based fertility tests support detecting challenges with fertility, like hormonal imbalances, poor semen quality, or low egg count. Lab tests do more than diagnose. They help in prognostication, detecting the likelihood of achievement with natural or assisted reproductive procedures, such as in vitro fertilization (IVF).
By gender, the female fertility diagnostics segment contributed the largest U.S. fertility diagnostic market share of 65%, as diagnostic test supports to detect problems early and give women a significant chance to become mothers. Early diagnosis provides emotional advantages, lessens frustration and stress, while guiding couples through suitable treatment options.
By end user, the fertility clinics segment contributed the largest market share of 38%, as these clinics have outstanding fertility management methods, and childless couples do opt for them. The specialists at a fertility clinic have the necessary expertise. A fertility clinic focuses on outstanding treatment processes apart from predictable treatment.
Leading companies in the U.S. fertility diagnostic market include Natera, Agilent Technologies, Invitae, and GeneDx. Meanwhile, Natera, a frontrunner in women’s health diagnostics, is known for its non-invasive prenatal diagnostics. Agilent Technologies offers advanced genomic instrumentation and assays that allow fertility clinics and diagnostic labs to identify genetic incongruities. Invitae offers comprehensive genetic screening and counselling in the infertility spectrum. GeneDx, known for whole-exome sequencing and progressive diagnostics regarding hereditary reproductive situations.
By Product Type
By Test Type
By Mode of Testing
By Gender
By End User
By Distribution Channel
